Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors

Guido Rindi, Donatella Paolotti, Roberto Fiocca, Bertram Wiedenmann, Jean Pierre Henry, Enrico Solcia

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The vesicular monoamine transporter 2 (VMAT2) facilitates the ATP-dependent accumulation of biogenic amine inside the secretory granules of endocrine cells and neurons and was demonstrated in the histamine-producing enterochromaffin-like (ECL) cells of the stomach. In the present investigation, VMAT2 immunohistochemistry was tested in 85 endocrine tumors, of which 60 were well differentiated gastrointestinal and pancreatic growths, 5 poorly differentiated (neuro)endocrine carcinomas (PDEC) and 1 mixed PDEC/ECL cell carcinoma of the stomach, 12 pheochromocytomas/paragangliomas, 3 adrenocortical lesions, 2 parathyroid and 2 lung neuroendocrine tumors. Extensive and intense VMAT2 immunoreactivity was observed in 16 of 16 gastric ECL cell tumors, 6 of 6 adrenal pheochromocytomas, 2 of 2 chromaffin paragangliomas and in 3 of the 4 carotid body paragangliomas investigated. Rare VMAT2-positive cells were observed in 12 of 21 intestinal enterochromaffin (EC) cell tumors, in 9 of 11 pancreatic neuroendocrine tumors, and in the mixed PDEC/ECL cell carcinoma of the stomach (differentiated cells only). No VMAT2 immunoreactivity was observed in five gastrin, four somatostatin and three enteroglucagon/peptideYY tumors of the gastrointestinal tract, in six gastric PDECs, in three adrenocortical growths, and two parathyroid and two lung neuroendocrine tumors. These data support VMAT2 immunohistochemistry as being a useful tool for the diagnosis of gastric ECL cell tumors, separating them from all other endocrine tumors arising in the gastroduodenal area i.e., gastrin, somatostatin, EC cell and PDEC tumors, all of which proved essentially negative.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalVirchows Archiv
Volume436
Issue number3
Publication statusPublished - 2000

Fingerprint

Vesicular Monoamine Transport Proteins
Enterochromaffin-like Cells
Stomach
Neuroendocrine Tumors
Neoplasms
Enterochromaffin Cells
Gastrins
Pheochromocytoma
Carcinoma
Immunohistochemistry
Glucagon-Like Peptides
Carotid Body Tumor
Neuroendocrine Cells
Lung
Biogenic Amines
Endocrine Cells
Somatostatin-Secreting Cells
Secretory Vesicles
Growth
Somatostatin

Keywords

  • ECL cell
  • Immunohistochemistry
  • Stomach
  • Tumors
  • VMAT2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. / Rindi, Guido; Paolotti, Donatella; Fiocca, Roberto; Wiedenmann, Bertram; Henry, Jean Pierre; Solcia, Enrico.

In: Virchows Archiv, Vol. 436, No. 3, 2000, p. 217-223.

Research output: Contribution to journalArticle

Rindi, G, Paolotti, D, Fiocca, R, Wiedenmann, B, Henry, JP & Solcia, E 2000, 'Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors', Virchows Archiv, vol. 436, no. 3, pp. 217-223.
Rindi, Guido ; Paolotti, Donatella ; Fiocca, Roberto ; Wiedenmann, Bertram ; Henry, Jean Pierre ; Solcia, Enrico. / Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. In: Virchows Archiv. 2000 ; Vol. 436, No. 3. pp. 217-223.
@article{dc2d9d56ceb34407a2e948bf9f9e39cb,
title = "Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors",
abstract = "The vesicular monoamine transporter 2 (VMAT2) facilitates the ATP-dependent accumulation of biogenic amine inside the secretory granules of endocrine cells and neurons and was demonstrated in the histamine-producing enterochromaffin-like (ECL) cells of the stomach. In the present investigation, VMAT2 immunohistochemistry was tested in 85 endocrine tumors, of which 60 were well differentiated gastrointestinal and pancreatic growths, 5 poorly differentiated (neuro)endocrine carcinomas (PDEC) and 1 mixed PDEC/ECL cell carcinoma of the stomach, 12 pheochromocytomas/paragangliomas, 3 adrenocortical lesions, 2 parathyroid and 2 lung neuroendocrine tumors. Extensive and intense VMAT2 immunoreactivity was observed in 16 of 16 gastric ECL cell tumors, 6 of 6 adrenal pheochromocytomas, 2 of 2 chromaffin paragangliomas and in 3 of the 4 carotid body paragangliomas investigated. Rare VMAT2-positive cells were observed in 12 of 21 intestinal enterochromaffin (EC) cell tumors, in 9 of 11 pancreatic neuroendocrine tumors, and in the mixed PDEC/ECL cell carcinoma of the stomach (differentiated cells only). No VMAT2 immunoreactivity was observed in five gastrin, four somatostatin and three enteroglucagon/peptideYY tumors of the gastrointestinal tract, in six gastric PDECs, in three adrenocortical growths, and two parathyroid and two lung neuroendocrine tumors. These data support VMAT2 immunohistochemistry as being a useful tool for the diagnosis of gastric ECL cell tumors, separating them from all other endocrine tumors arising in the gastroduodenal area i.e., gastrin, somatostatin, EC cell and PDEC tumors, all of which proved essentially negative.",
keywords = "ECL cell, Immunohistochemistry, Stomach, Tumors, VMAT2",
author = "Guido Rindi and Donatella Paolotti and Roberto Fiocca and Bertram Wiedenmann and Henry, {Jean Pierre} and Enrico Solcia",
year = "2000",
language = "English",
volume = "436",
pages = "217--223",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors

AU - Rindi, Guido

AU - Paolotti, Donatella

AU - Fiocca, Roberto

AU - Wiedenmann, Bertram

AU - Henry, Jean Pierre

AU - Solcia, Enrico

PY - 2000

Y1 - 2000

N2 - The vesicular monoamine transporter 2 (VMAT2) facilitates the ATP-dependent accumulation of biogenic amine inside the secretory granules of endocrine cells and neurons and was demonstrated in the histamine-producing enterochromaffin-like (ECL) cells of the stomach. In the present investigation, VMAT2 immunohistochemistry was tested in 85 endocrine tumors, of which 60 were well differentiated gastrointestinal and pancreatic growths, 5 poorly differentiated (neuro)endocrine carcinomas (PDEC) and 1 mixed PDEC/ECL cell carcinoma of the stomach, 12 pheochromocytomas/paragangliomas, 3 adrenocortical lesions, 2 parathyroid and 2 lung neuroendocrine tumors. Extensive and intense VMAT2 immunoreactivity was observed in 16 of 16 gastric ECL cell tumors, 6 of 6 adrenal pheochromocytomas, 2 of 2 chromaffin paragangliomas and in 3 of the 4 carotid body paragangliomas investigated. Rare VMAT2-positive cells were observed in 12 of 21 intestinal enterochromaffin (EC) cell tumors, in 9 of 11 pancreatic neuroendocrine tumors, and in the mixed PDEC/ECL cell carcinoma of the stomach (differentiated cells only). No VMAT2 immunoreactivity was observed in five gastrin, four somatostatin and three enteroglucagon/peptideYY tumors of the gastrointestinal tract, in six gastric PDECs, in three adrenocortical growths, and two parathyroid and two lung neuroendocrine tumors. These data support VMAT2 immunohistochemistry as being a useful tool for the diagnosis of gastric ECL cell tumors, separating them from all other endocrine tumors arising in the gastroduodenal area i.e., gastrin, somatostatin, EC cell and PDEC tumors, all of which proved essentially negative.

AB - The vesicular monoamine transporter 2 (VMAT2) facilitates the ATP-dependent accumulation of biogenic amine inside the secretory granules of endocrine cells and neurons and was demonstrated in the histamine-producing enterochromaffin-like (ECL) cells of the stomach. In the present investigation, VMAT2 immunohistochemistry was tested in 85 endocrine tumors, of which 60 were well differentiated gastrointestinal and pancreatic growths, 5 poorly differentiated (neuro)endocrine carcinomas (PDEC) and 1 mixed PDEC/ECL cell carcinoma of the stomach, 12 pheochromocytomas/paragangliomas, 3 adrenocortical lesions, 2 parathyroid and 2 lung neuroendocrine tumors. Extensive and intense VMAT2 immunoreactivity was observed in 16 of 16 gastric ECL cell tumors, 6 of 6 adrenal pheochromocytomas, 2 of 2 chromaffin paragangliomas and in 3 of the 4 carotid body paragangliomas investigated. Rare VMAT2-positive cells were observed in 12 of 21 intestinal enterochromaffin (EC) cell tumors, in 9 of 11 pancreatic neuroendocrine tumors, and in the mixed PDEC/ECL cell carcinoma of the stomach (differentiated cells only). No VMAT2 immunoreactivity was observed in five gastrin, four somatostatin and three enteroglucagon/peptideYY tumors of the gastrointestinal tract, in six gastric PDECs, in three adrenocortical growths, and two parathyroid and two lung neuroendocrine tumors. These data support VMAT2 immunohistochemistry as being a useful tool for the diagnosis of gastric ECL cell tumors, separating them from all other endocrine tumors arising in the gastroduodenal area i.e., gastrin, somatostatin, EC cell and PDEC tumors, all of which proved essentially negative.

KW - ECL cell

KW - Immunohistochemistry

KW - Stomach

KW - Tumors

KW - VMAT2

UR - http://www.scopus.com/inward/record.url?scp=0034065048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034065048&partnerID=8YFLogxK

M3 - Article

C2 - 10782879

AN - SCOPUS:0034065048

VL - 436

SP - 217

EP - 223

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 3

ER -